Does aspirin interfere with the therapeutic efficacy of angiotensin- converting enzyme inhibitors in hypertension or congestive heart failure?

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1041-1052

  Nawarskas, James J ^a,b   Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HYPERTENSION; MEDICAL INFORMATION; MEDICAL LITERATURE; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CARDIOTONIC AGENTS; CLINICAL TRIALS; DRUG ANTAGONISM; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION;

EID: 0031706499     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308: 81-106.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
6. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
7. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. Clin Exp Hypertens 1992;A14:307-31.
8. Vinci JM, Horwitz D, Zusman RM, Pisano JJ, Catt KJ, Reiser HR. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1979;1:416-26.
9. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J Clin Invest 1980;65:1257-64.
10. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
11. Williams GH, Dluhy RG. Control of aldosterone secretion. In: Genest J, Kuchel O, Hamet P, Cantin M, eds. Hypertension: physiopathology and treatment, 2nd ed. New York: McGraw-Hill, 1983:320-38.
12. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol 1993;264:E631-7.
13. Schrôr K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(suppl 9):S68-73.
14. Mason DT, Melmon KL. Effects of bradykinin on forearm venous tone and vascular resistance in man. Circ Res 1965;17:106-13.
15. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
16. 2 synthesis in vitro: possible mechanism of antihypertensive action [abstr]. Clin Res 1981;29:362A.
17. Luque M, Martin P, Martell N, Femandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805.
18. Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987;10(suppl 1):13-23.
19. Crantz FR, Swartz SL, Hollenberg NK, et al. Role of prostaglandins in the hypotensive response to captopril in essential hypertension [abstr]. Clin Res 1979;27:592A.
20. Abe K, Ito T, Sato M, et al. Role of prostaglandin in the antihypertensive mechanism of captopril in low renin hypertension. Clin Sci 1980;59(suppl 6):141s-4.
21. Fujita T, Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients. Clin Exp Hypertens 1981;3:939-52.
22. Goldstone R, Martin K, Zipser R, Horton R. Evidence for a dual action of converting enzyme inhibitor on blood pressure in normal man. Prostaglandins 1981;22:587-98.
23. Moore TJ, Crantz FR, Hollenberg NK, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-73.
24. Ogihara T, Maruyama A, Hata T, et al. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther 1981;30:328-35:
25. Salvetti A, Pedrinelli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to captopril in patients with essential hypertension. Clin Sci 1982;63(suppl 8):261s-3.
26. Silberbauer K, Stanek B, Tempi H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982;14(suppl 2):87S-93.
27. Swartz SL, Williams GH. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol 1982;49:1405-9.
28. Witzgall H, Scherer B, Weber PC. Involvement of prostaglandins in the actions of captopril. Clin Sci 1982;63(suppl 8):265s-7.
29. Lechi A, Covi G, Capuzzo MG, et al. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels. Int J Clin Pharmacol Ther Toxicol 1983;21: 569-74.
30. Covi G, Minuz P, Capuzzo G, Lechi C, Delva P, Lechi A. Reduction of the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition. Int J Clin Pharm Res 1984;4:47-52.
31. Santucci A, Aguglia F, De Mattia G, et al. Effects of captopril on blood pressure and renin-angiotensin-aldosterone system in hypertensive subjects after inhibition of renal vasodilative system. Int J Clin Pharm Res 1984;4:41-5.
32. 2 to the antihypertensive mechanism of ACE inhibitors. Adv Prostaglandin Thromboxane Leukot Res 1985;13:199-202.
33. Minuz P, Lechi A, Arosio E, et al. Antihypertensive activity of enalapril. Effect of ibuprofen and different salt intakes. J Clin Hypertens 1987;3:645-53.
34. Omata K, Abe K, Tsunoda K, et al. Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension. Clin Exp Hypertens 1987;A9:569-74.
35. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK. Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin. Am J Med Sci 1987;294:395-402.
36. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK, Dustan HP. Antihypertensive effect of enalapril (MK-421) in low renin essential hypertension: role of vasodilator prostaglandins [abstr]. Clin Res 1983;31:538A.
37. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987;5:121-8.
38. Salvetti A, Abdel-Haq B, Magagna A, Pedrinelli R. Indomethacin reduces the antihypertensive action of enalapril. Clin Exp Hypertens 1987;A9:559-67.
39. Seto S, Aoi W, Iwami K, et al. Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension. Clin Exp Hypertens 1987;A9:623-7.
40. Shaw W, Shapiro D, Antonello J, Cressman M, Vlasses P, Oparil S. Indomethacin does not blunt the antihypertensive effect of lisinopril [abstr]. Clin Pharmacol Ther 1987;41:219.
41. Gilchrist NL, Richards AM, March R, Nicholls MG. Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens 1989;3:451-5.
42. Lucarini AR, Abdel-Haq B, Arrighi P, Magagna A, Favilla S, Salvetti A. Are prostaglandins involved in the systemic and renal hemodynamic actions of lisinopril? [abstr]. Am J Hypertens 1989;2:113A.
43. Koopmans PP, van Megen T, Thien T, Gribnau FWJ. The interaction between indomethacin and captopril or enalapril in healthy volunteers. J Intern Med 1989;226:139-42.
44. Kirch W, Stroemer K, Hoogkamer JFW, Kleinbloesem CH. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril. Br J Clin Pharmacol 1989;27:297S-301.
45. Abdel-Haq B, Magagna A, Favilla S, Salvetti A. Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects. J Cardiovasc Pharmacol 1991;18(suppl 7):S33-6.
46. Cusson JR, Du Souich P, Le Morvan P, et al. Effect of ketoprofen on blood pressure, endocrine and renal responses to chronic dosing with captopril in patients with essential hypertension. Blood Pressure 1992;1:162-7.
47. Gerber JG, Franca G, Byyny RL, LoVerde M, Nies AS. The hypotensive action of captopril and enalapril is not prostacyclin dependent. Clin Pharmacol Ther 1993;54:523-32.
48. Morgan T, Andersen A. Interaction of indomethacin with felodipine and enalapril. J Hypertens 1993;11(suppl 5):S338-9.
49. Polónia J, Boaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995;13:925-31.
50. Pancera P, Arosio E, Minuz P, Pirante F, Ribul M, Lechi A. Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 1996;54:217-22.
51. Pritchard G, Lyons D, Webster J, Petrie JC, MacDonald TM. Indomethacin does not attenuate the hypotensive effect of trandolapril. J Hum Hypertens 1996;10:763-7.
52. Smith SR, Coffman TM, Svetkey LP. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993;4:1133-9.
53. Magagna A, Abdel-Haq B, Favilla S, Taddei S, Salvetti A. Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Pressure 1994;3:236-41.
54. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998;63:79-86.
55. Böger RH, Bode-Böger SM, Kramme P, Tsikas D, Gutzki FM, Frölich JC. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol 1996;42:721-7.
56. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645-51.
57. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
58. Townend JN, Doran J, Lote CJ, Davies MK. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J 1995;73:434-41.
59. Gottlieb SS, Robinson S, Krichten CM, Fisher ML. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70:890-3.
60. Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989;117:100-5.
61. Schwartz D, Kornowski R, Lehrman H, et al. Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. Cardiology 1992;81:334-9.
62. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
63. van Wijngaarden J, Smit AJ, de Graeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994;23:240-5.
64. Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
65. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997;95:1930-6.
66. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
67. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-19.
68. Leor J, Reicher-Reiss H, Goldbourt U, et al. Is it safe to prescribe aspirin to patients on ACE-inhibitors? [abstr]. J Am Coll Cardiol 1997;29(suppl A):370A.
69. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996;51:179-87.
70. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharmacol 1990;30:519-26.
71. Catella F, Nowak J, FitzGerald GA. Measurement of renal and non-renal eicosanoid synthesis. Am J Med 1986;81(suppl 2B):23-9.
72. Guivernau M, Armijo F, Rosas R. Role of sulfhydryl groups in the stimulatory effect of captopril on vascular prostacyclin synthesis. Eur J Pharmacol 1991;198:1-6.
73. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther 1991;257: 1136-45.
74. Simon LS, Mills JA. Nonsteroidal antiinflammatory drugs. N Engl J Med 1980;302:1179-85.
75. Insel PA. Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990:638-81.
76. Ciabattoni G, Cinotti GA, Pierucci A, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984;310:279-83.
77. McMahon FG, Jain AK, Vargas R, Ryan M, Ryan JR. Does sulindac attenuate pressure control among hypertensives? Curr Ther Res 1989;45:143-51.
78. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.
79. FitzGerald GA, Dates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983;71:676-88.
80. 2. J Assoc Physicians India 1995;43:597-9.
81. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24(suppl 49):6-8.
82. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997;24(suppl 49):20-4.
83. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors. A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996;25:363-72.
84. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-14.
85. Hansson L. The optimal blood pressure reduction. J Hypertens 1996;14(suppl 2):S55-8.
86. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-19.